Literature DB >> 1497570

Alterations of the force-frequency relationship in the failing human heart depend on the underlying cardiac disease.

B Pieske1, G Hasenfuss, C Holubarsch, R Schwinger, M Böhm, H Just.   

Abstract

We investigated the force-frequency relationship (0.5-3 Hz) in non-failing human myocardium and in end-stage failing human myocardium due to dilated cardiomyopathy or subacute myocarditis. In non-failing myocardium, force of contraction increased with increasing stimulation frequency. In end-stage heart failure, the force-frequency relationship was inverse in myocardium from dilated cardiomyopathy, but was similar to control in myocardium from subacute myocarditis. After increasing extracellular Ca(2+)-concentration from 2.5 to 7.2 mM, the shape of the force-frequency relationship was not changed in nonfailing myocardium. In dilated cardiomyopathy, the decline in force with increasing frequencies was even more pronounced at 7.2 mM compared to 2.5 mM extracellular Ca2+. In subacute myocarditis, at Ca2+ 7.2 mM, increasing frequencies increased force in the lower frequency range (less than 1.75 Hz) only, whereas at higher stimulation rates force declined again. These results indicate that (1.) alterations of the force-frequency relationship in the failing human heart depend on the underlying cardiac disease and/or the time-course of the disease, and (2.) an increase in the extracellular Ca(2+)-concentration aggravates changes in the force-frequency relationship in the failing myocardium.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1497570     DOI: 10.1007/978-3-642-72474-9_17

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  8 in total

1.  Diminished post-rest potentiation of contractile force in human dilated cardiomyopathy. Functional evidence for alterations in intracellular Ca2+ handling.

Authors:  B Pieske; M Sütterlin; S Schmidt-Schweda; K Minami; M Meyer; M Olschewski; C Holubarsch; H Just; G Hasenfuss
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

2.  Effect of pimobendan in patients with chronic heart failure.

Authors:  N Takeda; Y Hayashi; T Arino; A Takeda; K Noma
Journal:  Exp Clin Cardiol       Date:  2001

3.  Sarcoplasmic reticulum calcium mobilization in right ventricular pressure-overload hypertrophy in the ferret: relationships to diastolic dysfunction and a negative treppe.

Authors:  J K Gwathmey; J P Morgan
Journal:  Pflugers Arch       Date:  1993-03       Impact factor: 3.657

4.  Uniformity of calcium channel number and isometric contraction in human right and left ventricular myocardium.

Authors:  E J Gruver; J P Morgan; B S Stambler; J K Gwathmey
Journal:  Basic Res Cardiol       Date:  1994 Mar-Apr       Impact factor: 17.165

5.  Biowire Model of Interstitial and Focal Cardiac Fibrosis.

Authors:  Erika Yan Wang; Naimeh Rafatian; Yimu Zhao; Angela Lee; Benjamin Fook Lun Lai; Rick Xingze Lu; Danica Jekic; Locke Davenport Huyer; Ericka J Knee-Walden; Shoumo Bhattacharya; Peter H Backx; Milica Radisic
Journal:  ACS Cent Sci       Date:  2019-06-04       Impact factor: 14.553

6.  K201 improves aspects of the contractile performance of human failing myocardium via reduction in Ca2+ leak from the sarcoplasmic reticulum.

Authors:  Karl Toischer; Stephan E Lehnart; Gero Tenderich; Hendrik Milting; Reiner Körfer; Jan D Schmitto; Friedrich A Schöndube; Noboru Kaneko; Christopher M Loughrey; Godfrey L Smith; Gerd Hasenfuss; Tim Seidler
Journal:  Basic Res Cardiol       Date:  2009-08-30       Impact factor: 17.165

Review 7.  SERCA2a gene therapy in heart failure: an anti-arrhythmic positive inotrope.

Authors:  Markus B Sikkel; Carl Hayward; Kenneth T MacLeod; Sian E Harding; Alexander R Lyon
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

8.  The contractile adaption to preload depends on the amount of afterload.

Authors:  Hanna Schotola; Samuel T Sossalla; André Renner; Jan Gummert; Bernhard C Danner; Peter Schott; Karl Toischer
Journal:  ESC Heart Fail       Date:  2017-04-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.